<DOC>
	<DOCNO>NCT02339116</DOCNO>
	<brief_summary>Bev improve efficacy first-line chemotherapy unresectable mCRC . In phase III TRIBE trial upfront FOLFOXIRI plus bev provide significant advantage term PFS RR compare FOLFIRI plus bev . A trend toward good OS also evidence . The second-line treatment investigator 's choice . A manageable increase diarrhea , mucositis neutropenia report , difference febrile neutropenia , serious adverse event toxic death evidence . A grow amount data support clinical relevance achieve early deep tumor shrinkage . Phase III TML BEBYP trial demonstrate continuation bev beyond disease progression combine switch chemotherapy regimen provide significant advantage term OS PFS . Based recent evidence , partial interruption upfront `` induction '' chemotherapy disease progression prosecution bev disease progression maintenance treatment valid strategy treatment mCRC . On basis consideration , first-line doublet plus bev follow second-line switched doublet ( oxaliplatin irinotecan viceversa ) plus bev consider standard option mCRC patient . Only retrospectively collect data currently available efficacy first-line FOLFOXIRI plus bev follow second-line rechallenge FOLFOXIRI plus bev . We therefore design present phase III randomize trial first-line FOLFOXIRI plus bev follow reintroduction FOLFOXIRI plus bev progression versus FOLFOX plus bev follow FOLFIRI plus bev progression first- second-line treatment unresectable mCRC patient .</brief_summary>
	<brief_title>Folfoxiri Plus Bev Followed Reintroduction Folfoxiri Plus Bev Progression Versus Folfox Plus Bev Followed Folfiri Plus Bev mCRC</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>Main Histologically proven diagnosis colorectal cancer Initially unresectable metastatic colorectal cancer previously treat chemotherapy metastatic disease At least one measurable lesion accord RECIST1.1 criterion Availability tumoral sample Male female 1875 year age ECOG PS &lt; = 2 age &lt; 71 year , ECOG PS = 0 aged 7175 year Life expectancy least 12 week Previous adjuvant chemotherapy allow fluoropyrimidine monotherapy 6 month elapse end adjuvant first relapse Neutrophils &gt; 1.5 x 109/L , Platelets &gt; 100 x 109/L , Hgb &gt; 9 g/dl Total bilirubin 1.5 time uppernormal limit ( UNL ) normal value ASAT ( SGOT ) and/or ALAT ( SGPT ) &lt; 2.5 x UNL ( &lt; 5 x UNL case liver metastasis ) alkaline phosphatase &lt; 2.5 x UNL ( &lt; 5 x UNL case liver metastasis ) Creatinine clearance &gt; 50 mL/min serum creatinine 1.5 x UNL Urine dipstick proteinuria &lt; 2+ . Patients discover 2+ proteinuria dipstick urinalysis baseline , undergo 24hour urine collection must demonstrate &lt; 1 g protein/24 hr Will ability comply protocol Written inform consent study procedure molecular analysis Main Radiotherapy site within 4 week study Previous adjuvant oxaliplatincontaining chemotherapy Previous treatment bevacizumab Untreated brain metastasis spinal cord compression primary brain tumour History evidence upon physical examination CNS disease unless adequately treat Symptomatic peripheral neuropathy &gt; 2 grade NCICCTG criterion Serious , nonhealing wound , ulcer , bone fracture Evidence bleed diathesis coagulopathy Uncontrolled hypertension prior histor hypertensive crisis hypertensive encephalopathy Clinically significant ( i.e . active ) cardiovascular disease example cerebrovascular accident ( ≤6 month ) , myocardial infarction ( ≤6 month ) , unstable angina , New York Heart Association ( NYHA ) grade II great congestive heart failure , serious cardiac arrhythmia require medication Significant vascular disease ( e.g . aortic aneurysm require surgical repair recent arterial thrombosis ) within 6 month study enrolment Any previous venous thromboembolism &gt; NCI CTCAE Grade 3 History abdominal fistula , GI perforation , intraabdominal abscess active GI bleeding within 6 month prior first study treatment . Current recent ( within 10 day prior study treatment start ) ongoing treatment anticoagulant therapeutic purpose Chronic , daily treatment highdose aspirin ( &gt; 325 mg/day ) Treatment investigational drug within 30 day prior enrollment 2 investigational agent halflives ( whichever longer ) Other coexist malignancy malignancy diagnose within last 5 year exception localize basal squamous cell carcinoma cervical cancer situ Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior study treatment start , anticipation need major surgical procedure course study Lack physical integrity upper gastrointestinal tract , malabsorption syndrome , inability take oral medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>